Pseudodeficiency of glutamine in infant liver disease

T Vermeulen1, T Marquardt, J Häberle

  • 1Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Münster, Albert-Schweitzer-Strasse 33, 48129 Münster, Germany.

Amino Acids
|July 25, 2008
PubMed

Insights

Elevated gamma-glutamyltransferase (gamma-GT) in infants can falsely lower serum glutamine levels, mimicking a deficiency. Physicians should notify labs of high gamma-GT to prevent misdiagnosis.

Area of Science:

  • Biochemistry
  • Clinical Chemistry
  • Pediatric Medicine

Background:

  • Gamma-glutamyltransferase (gamma-GT) is a key enzyme in amino acid metabolism.
  • Elevated serum gamma-GT is an established early indicator of cholestasis.
  • Gamma-GT possesses glutamine-deamidating activity.

Purpose of the Study:

  • To investigate the effect of elevated gamma-GT on serum glutamine levels in infants.
  • To determine if increased gamma-GT activity can lead to a pseudodeficiency of glutamine.
  • To analyze the time-dependent changes in glutamine and glutamate concentrations.

Main Methods:

  • Serum samples from infants with elevated gamma-GT were analyzed.
  • Time-course studies were conducted to measure glutamine and glutamate concentrations.
  • In vitro experiments assessed the impact of gamma-GT on glutamine deamidation.

Main Results:

  • Infants with elevated serum gamma-GT exhibited decreased serum glutamine levels.
  • Time-dependent studies showed a significant drop in glutamine below normal limits.
  • Concurrently, glutamate levels increased above normal upper limits.

Conclusions:

  • Increased gamma-glutamyltransferase activity in vitro can induce a pseudodeficiency of serum glutamine.
  • Physicians must inform clinical laboratories about accompanying pathologies like elevated gamma-GT to avoid diagnostic errors.
  • Accurate interpretation of serum glutamine levels requires consideration of concurrent gamma-GT activity.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Protein Import into the Peroxisomes01:27

Protein Import into the Peroxisomes

Cells contain membrane-bound organelles called peroxisomes that oxidize organic molecules by transferring hydrogen atoms to oxygen, producing hydrogen peroxide. Peroxisomes enzymatically convert the released hydrogen peroxide into water and oxygen.
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...